fulcrumtx.com (FULC) Quarterly EPS earnings growth

Symbol and logo of brand Fulcrum Corp (FULC)

Fulcrum Therapeutics (FULC) is developing therapies for orphan diseases through genetic alliances and targeted deals to acquire drug rights. The quarterly earnings per share growth rate provided by GURU.Markets data reflects a trend where the 53.80 mark indicates the current yield level. Fulcrum Therapeutics adheres to ESG standards for emissions filtration and delegates molecule synthesis to vetted CRO contractors.

FULC: Fulcrum Therapeutics, Inc. Year-over-year earnings per one share growth for the last 12 months 07/04/2022 - 11/17/2026

Fulcrum Therapeutics (FULC) - metric breakdowns and financial figures

- share price and expert price forecast:
Initial company analysis:Fulcrum Therapeutics
Flagship merchandise of Fulcrum Corp

Quarterly EPS growth measures the dynamics of net income per share, reflecting the efficiency of business capitalization. Comparing current values with historical data allows an investor to filter out market noise and determine the asset's real value. By analyzing the trajectory of quarterly EPS changes, one can identify cyclical profitability patterns. For Fulcrum Therapeutics (FULC), this indicator confirms financial stability during the development of high-cost drugs. Growth in this metric signals the company's ability to monetize treatments for rare genetic pathologies.

Who Fulcrum Therapeutics competes with

VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alnylam Inc. (ALNY)|INSM (Insmed) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months UTHR (United Therapeutics Corporation)|Year-over-year net earnings per share growth for the last 12 months BMRN (BioMarin)|BBIO (BridgeBio Pharma) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth BGM (BGM Group Ltd)|COGT (Cogent Bio) - Year-over-year net earnings per share trend for the last twelve months|Xeris Biopharma - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months KROS (Keros Therapeutics)|ARCT: Quarterly EPS earnings growth|Eton Pharmaceuticals Inc (ETON) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Kamada Corp|ABEO: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Mereo BioPharma Group (MREO)|Quarterly EPS earnings growth protalix.com (PLX)|Quarterly EPS earnings growth PLRX (Pliant Therapeutics Inc)|Quarterly EPS earnings growth Applied Therapeutics APLT|RNTX - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year gelteq.com (GELS)|AYTU (aytubio.com) - Year-over-year net earnings per share growth for the last 12 months|Chemomab Therapeutics Ltd - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SRXH|Year-over-year earnings per share growth for the last twelve months PLRZ|Quarterly EPS earnings growth AEZS|Year-over-year earnings per share growth for the last twelve months CYTH (Cyclo Therapeutics, Inc)|Inozyme Pharma - Year-over-year net earnings per share growth for the last 12 months|Reneo Pharmaceuticals, Inc. (RPHM) - Earnings per share growth in annualized terms for the last twelve months|COSCIENS Bio - Quarterly EPS earnings growth